Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-fluoroestradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer
2019-002665-35Phase 2Completed
- Sponsor
- Mikkel Holm Vendelbo
- Start
- Sep 2019
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluoroestradiol f 18 in breast cancer, sponsored by Mikkel Holm Vendelbo. Primary endpoint: Sensitivity of parametric vs conventional FES-PET/CT for detection of ER-positive liver metastases. Started Sep 2019; status: completed.
02
Drugs
fluoroestradiol f 18
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-002665-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002665-35.